Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36


Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.

Jin Q, Yuan LX, Boulbes D, Baek JM, Wang YN, Gomez-Cabello D, Hawke DH, Yeung SC, Lee MH, Hortobagyi GN, Hung MC, Esteva FJ.

Breast Cancer Res. 2010;12(6):R96. doi: 10.1186/bcr2777. Epub 2010 Nov 16.


Structure and function of eukaryotic fatty acid synthases.

Maier T, Leibundgut M, Boehringer D, Ban N.

Q Rev Biophys. 2010 Aug;43(3):373-422. doi: 10.1017/S0033583510000156. Epub 2010 Aug 24. Review.


Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma.

Uddin S, Hussain AR, Ahmed M, Bu R, Ahmed SO, Ajarim D, Al-Dayel F, Bavi P, Al-Kuraya KS.

Mol Cancer Ther. 2010 May;9(5):1244-55. doi: 10.1158/1535-7163.MCT-09-1061. Epub 2010 Apr 27.


How I treat mantle cell lymphoma.

Ghielmini M, Zucca E.

Blood. 2009 Aug 20;114(8):1469-76. doi: 10.1182/blood-2009-02-179739. Epub 2009 Jun 25. Review.


De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy.

Mashima T, Seimiya H, Tsuruo T.

Br J Cancer. 2009 May 5;100(9):1369-72. doi: 10.1038/sj.bjc.6605007. Epub 2009 Apr 7. Review.


Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.

Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, Loda M.

J Natl Cancer Inst. 2009 Apr 1;101(7):519-32. doi: 10.1093/jnci/djp030. Epub 2009 Mar 24.


Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer.

Fiorentino M, Zadra G, Palescandolo E, Fedele G, Bailey D, Fiore C, Nguyen PL, Migita T, Zamponi R, Di Vizio D, Priolo C, Sharma C, Xie W, Hemler ME, Mucci L, Giovannucci E, Finn S, Loda M.

Lab Invest. 2008 Dec;88(12):1340-8. doi: 10.1038/labinvest.2008.97. Epub 2008 Oct 6.


Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma.

Gelebart P, Anand M, Armanious H, Peters AC, Dien Bard J, Amin HM, Lai R.

Blood. 2008 Dec 15;112(13):5171-9. doi: 10.1182/blood-2008-02-139212. Epub 2008 Sep 11.


Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers.

Uddin S, Siraj AK, Al-Rasheed M, Ahmed M, Bu R, Myers JN, Al-Nuaim A, Al-Sobhi S, Al-Dayel F, Bavi P, Hussain AR, Al-Kuraya KS.

J Clin Endocrinol Metab. 2008 Oct;93(10):4088-97. doi: 10.1210/jc.2008-0503. Epub 2008 Aug 5.


Increased fatty acid synthase as a potential therapeutic target in multiple myeloma.

Wang WQ, Zhao XY, Wang HY, Liang Y.

J Zhejiang Univ Sci B. 2008 Jun;9(6):441-7. doi: 10.1631/jzus.B0740640.


Mantle cell lymphoma: advances in biology and therapy.

Smith MR.

Curr Opin Hematol. 2008 Jul;15(4):415-21. doi: 10.1097/MOH.0b013e328302c9c5. Review.


Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways.

Rizzatti EG, Mora-Jensen H, Weniger MA, Gibellini F, Lee E, Daibata M, Lai R, Wiestner A.

Leuk Lymphoma. 2008 Apr;49(4):798-808. doi: 10.1080/10428190801910912. Erratum in: Leuk Lymphoma. 2016 May;57(5):1245.


Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels.

Tucker CA, Kapanen AI, Chikh G, Hoffman BG, Kyle AH, Wilson IM, Masin D, Gascoyne RD, Bally M, Klasa RJ.

Mol Cancer Ther. 2008 Apr;7(4):749-58. doi: 10.1158/1535-7163.MCT-07-0302. Epub 2008 Mar 28.


Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells.

Pallasch CP, Schwamb J, Königs S, Schulz A, Debey S, Kofler D, Schultze JL, Hallek M, Ultsch A, Wendtner CM.

Leukemia. 2008 Mar;22(3):585-92. Epub 2007 Dec 13.


Fatty acid synthase inhibitors: new directions for oncology.

Kridel SJ, Lowther WT, Pemble CW 4th.

Expert Opin Investig Drugs. 2007 Nov;16(11):1817-29. Review.


Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.

Jares P, Colomer D, Campo E.

Nat Rev Cancer. 2007 Oct;7(10):750-62. Review.


Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis.

Menendez JA, Lupu R.

Nat Rev Cancer. 2007 Oct;7(10):763-77. Review.


Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells.

Yoon S, Lee MY, Park SW, Moon JS, Koh YK, Ahn YH, Park BW, Kim KS.

J Biol Chem. 2007 Sep 7;282(36):26122-31. Epub 2007 Jul 13.


Supplemental Content

Support Center